Silo Pharma, Inc. Annual Report: A Plain-English Guide

I’ve put together this guide to help you understand how Silo Pharma performed this year. My goal is to turn complex filing data into clear information so you can decide if this company fits your investment strategy.

1. What does this company do?

Silo Pharma is a startup in the lab phase. They aren't selling finished medicines yet. Instead, they research treatments for PTSD, anxiety, fibromyalgia, and Alzheimer’s. They focus on traditional drug development and psychedelic-based therapies, such as ketamine and psilocybin. They also hold Solana (SOL) cryptocurrency as part of their corporate treasury strategy.

2. Financial performance

Silo has not yet turned a profit. For the year ending December 31, 2023, the company reported $0 in revenue because they are still in the early research stage. Operating expenses reached $4.3 million, primarily driven by research and administrative costs.

The company holds about $2.6 million in cash. With a monthly burn rate of $300,000 to $400,000, the company relies on raising capital by selling additional shares. Investors should be aware that this process increases the total number of shares, which reduces the ownership percentage of existing shareholders.

3. Major wins and progress

The company is moving four main drug candidates forward:

• SPC-15 (PTSD/Anxiety): This is their lead program, which utilizes a specialized nasal spray. In 2024, the company reached an agreement with the FDA on a faster approval path. Safety studies began in early 2025, with plans to request permission for human trials in 2026.
• SP-26 (Fibromyalgia/Pain): This program focuses on a ketamine implant designed for long-term pain relief as an alternative to opioids. Initial development is complete, and animal studies began in early 2025.
• Additional Pipeline: The company continues to research Alzheimer’s and psilocybin-based treatments, which remain in the early discovery phase.

4. Key risks

Investing in Silo is highly speculative. Consider these factors before making a decision:

• Capital Requirements: With roughly 7–9 months of cash runway, the company will need to raise more money soon. This will likely lead to further dilution of your shares.
• Regulatory Hurdles: Because they work with controlled substances, any changes in DEA regulations or a denial of clinical trial requests from the FDA would significantly impact their ability to continue operations.
• Digital Asset Volatility: Holding Solana introduces risks related to market volatility, potential security breaches, or regulatory actions from the SEC, which could negatively impact the company's financial position.
• Development Uncertainty: The company has never brought a drug to market. Most biotech firms face significant challenges when moving from lab research to human trials, and there is no guarantee their specific delivery systems will be effective in humans.

5. Future outlook

Silo is focused on hitting specific milestones for their four drug candidates over the next two years. Their primary objective is to complete the data packages required for FDA approval. Success hinges on their ability to prove their treatments are safe and their capacity to raise enough capital to reach the market.

A final thought for your decision: Silo Pharma is a high-risk, high-reward biotech play. Because they have no revenue and a limited cash runway, your investment is essentially a bet on their ability to successfully navigate FDA trials and manage their ongoing need for new capital. If you are considering an investment, ensure it aligns with your tolerance for the volatility typical of early-stage pharmaceutical development.